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Abstract
Although Fas (CD95) is recognized as a death receptor that induces apoptosis, recent studies indicate that the Fas/FasL 
system can induce pro-inflammatory cytokine production by macrophages independent of conventional caspase-
mediated apoptotic signaling. The precise mechanism(s) by which Fas activates macrophage inflammation is 
unknown. We hypothesized that Fas stimulates rapid release of high mobility group box 1 (HMGB1) that acts in an 
autocrine and/or paracrine manner to stimulate pro-inflammatory cytokine production via a Toll-like receptor-4 (TLR4)/
Interleukin-1 receptor associated kinase-4 (IRAK4)-dependent mechanism. Following Fas activation, HMGB1 was 
released within 1 hr from viable RAW267.4 cells and primary murine peritoneal macrophages. HMGB1 release was more 
rapid following Fas activation compared to LPS stimulation. Neutralization of HMGB1 with an inhibitory anti-HMGB1 
monoclonal antibody strongly inhibited Fas-induced production of tumor necrosis factor (TNF) and macrophage 
inflammatory protein-2 (MIP-2). Both Fas-induced HMGB1 release and associated pro-inflammatory cytokine 
production were significantly decreased from Tlr4-/- and Irak4-/- macrophages, but not Tlr2-/- macrophages. These 
findings reveal a novel mechanism underlying Fas-mediated pro-inflammatory physiological responses in 
macrophages. We conclude that Fas activation induces rapid, TLR4/IRAK4-dependent release of HMGB1 that 
contributes to Fas-mediated pro-inflammatory cytokine production by viable macrophages.
Introduction
Fas (CD95) is a 48-kDa, type I transmembrane protein
member of the TNF receptor family [1]. The endogenous
ligand for Fas is FasL (CD178), a 40-kDa, type II homotri-
meric transmembrane protein member of the TNF gene
family [1,2]. The Fas/FasL (APO-1/APO-1L; CD95/
CD95L) system was first reported, and is generally recog-
nized, as a major regulator of the extrinsic pathway of
caspase-dependent apoptosis [3-6]. Fas-mediated apop-
tosis has been extensively studied for its non- or anti-
inflammatory role in tissue injury and organ dysfunction
[7-9]. However, accumulating evidence indicates that Fas
can mediate myeloid differentiation factor 88 (MyD88)/
interleukin-1 receptor-associated kinase-4 (IRAK4)-
dependent pro-inflammatory responses via mechanisms
distinct from its role in apoptotic programmed cell death
[10-14].
HMGB1 protein was first described almost 30 years ago
as a non-histone chromosomal protein with high electro-
phoretic mobility [15,16]. As a DNA binding protein,
HMGB1 is involved in maintenance of nucleosome struc-
ture and regulation of gene transcription [17,18]. In addi-
tion to its role in regulation of transcription, HMGB1 has
been shown to activate pro-inflammatory responses
when released by necrotic cells into the extracellular
milieu [19]. HMGB1 has been implicated in the patho-
genesis of a number of diseases associated with inflam-
mation and tissue injury, including sepsis [20-23]. Recent
evidence indicates that HMGB1 can be released not only
from necrotic cells but also from activated macrophages
to act as an 'endogenous dangerous signal' or 'alarmin'
[24]. Several cognate cell surface receptors have been
proposed for HMGB1, including receptor for advanced
glycation end products (RAGE), TLR2 and TLR4 [25-27].
HMGB1-induced proinflammatory cytokine production
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by macrophages has been reported to be TLR4-depen-
dent [28-30].
I n  t h i s  s t u d y ,  w e  d e m o n s t r a t e  t h a t  a c t i v a t i o n  o f  F a s
induces rapid release of HMGB1 from a murine mac-
rophage (mϕ) cell line and primary murine peritoneal mϕ
that contributes to Fas-induced pro-inflammatory
cytokine production. Furthermore, using genetically
defined mice, we show that TLR4/IRAK4-dependent
mechanisms are involved in Fas-induced HMGB1 release
and pro-inflammatory cytokine production by mϕs.
These findings identify a novel mechanism for Fas-medi-
ated pro-inflammatory responses and implicate impor-




Recombinant mouse Fas ligand (CD178) was obtained
from R&D system (Minneapolis, MN, USA). Anti-mouse
Fas monoclonal antibody (mAb) Jo2 IgG2 was obtained
from BD Bioscience (Mississauga, ON Canada).
Lipopolysaccharide (LPS, Escherichia coli 0111:B4) was
obtained from Sigma (St Louis, MO, USA). Inhibitory
anti-HMGB1 neutralizing monoclonal antibody was pro-
vided by Dr. Huan Yang from the Feinstein Institute for
Medical Research (Manhasset, NY, USA) [30]. Mouse
IgG2b isotype control (R&D System, MN, USA) was used
as a negative control antibody.
Primary murine peritoneal macrophage isolation and 
culture
Animal use was performed in compliance with current
University of Toronto institutional guidelines, and animal
protocols were approved by the Animal Care Committee
of the University of Toronto. Peritoneal mϕ were
obtained by peritoneal lavage from wild type, Tlr2-/-,
Tlr4-/-,  Irak4-/- mice (all mice were maintained on the
C57BL/6 genetic background; age: 8-10 weeks; weight:
20-25 g) and Fas-deficient Faslpr mice (The Jackson Labo-
ratory, Maine, USA). Briefly, 10 ml of sterile RPMI was
injected into the peritoneal cavity, and the contents of the
cavity were gently massaged. A similar volume was then
removed from the abdomen, and 2 × 106 cells/well were
seeded in a volume of 2 ml/well in a 6-well tissue culture
plate.
Cell culture and treatment
The murine mϕ cell line RAW264.7 (American Type Cell
Collection, Rockville, MD, USA) and primary murine
peritoneal mϕ were maintained in RPMI 1640 (Sigma;
Mississauga, ON, Canada), containing 10% heat-inacti-
vated fetal bovine serum (FBS) (Sigma, Mississauga, ON,
Canada) supplemented with gentamicin reagent solution
(Invitrogen; Burlington, ON, Canada), at 37°C in 5%
CO2-enriched air. Cells (2 × 106/well) were plated in 6-
well tissue culture plates at a volume of 2 ml/well in RPMI
1640 containing 10% fetal bovine serum and pretreated
with or without inhibitory anti-HMGB1 neutralizing
monoclonal antibody (IgG2b mAb) (0.25 μg/ml) or a nega-
tive isotype (IgG2b) control (IgG2b) mAb (0.25 μg/ml).
Macrophages were stimulated with recombinant mouse
Fas ligand (mFasL, 0.25 μg/ml), or activating anti-murine
Fas mAb Jo2 (IgG2, 0.25 μg/ml), or LPS (0.25 μg/ml).
mFasL and mAb Jo2 were pretreated with Detoxi-Del™
Endotoxin Removing Gel (Pierce Biotech: Rockford, IL,
USA) to remove any contaminating LPS. Samples of cul-
ture supernatant were obtained at multiple time points.
Cell count and viability were determined microscopically
by 0.4% trypan blue dye exclusion. The concentration of
endotoxin in each wells were tested with Prostate LAL
(PSD10, MA, USA). In our experiments, clot formed only
in the LPS treated group indicating that endotoxin levels
in all other groups were less than 0.25 EU/ml.
Cell viability assay
Cell viability was determined by trypan blue exclusion
using a Vi-Cell XR Cell Analyzer (Beckman Coulter, CA,
USA).
Preparation of cellular extracts
Cells were harvested at the designated times and washed
twice with cold PBS; nuclear and cytoplasmic extracts
were prepared according to the method of Schreiber et al
[31]. Briefly, the cell pellets were resuspended in 400 μl
cold buffer A (10 mM HEPES, pH 7.9, 10 mM KCl, 0.1
mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF).
Cells were allowed to swell on ice for 15 min, after which
25 μl of a 10% solution of Nonidet P-40 was added, and
the tube was vortexed vigorously for 10 s. The lysate was
centrifuge at 4°C at 15000 g for 3 min, and the nuclear
pellet was resuspended in 50 μl ice-cold buffer B (20 mM
HEPES, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA,
1 mM DTT, 1 mM PMSF). After vigorously rocking at
4°C for 15 min on a shaking platform, the nuclear extract
was centrifuged for 5 min at 4°C, and the supernatant was
frozen at -80°C. The protein content of the different frac-
tions was determined by Bradford assay.
Concentration of conditioned cell culture medium
After incubation, cell medium were collected and con-
centrated 10-fold using a 7 ml ICON concentrator (Pierce
Biotechnology, Rockford, IL, USA) according to the man-
ufacturer's protocol. The final protein concentration of
cell medium of the negative control group was 5 μg/μl.
The concentrated samples were boiled for 5 min and used
for detection of HMGB1 by immunoblot analysis.Wang et al. Journal of Inflammation 2010, 7:30
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HMGB1 immunoblot analysis
Proteins in concentrated culture media and cell extracts
were resolved on 10% SDS-PAGE and transferred to a
polyvinylidene fluoride membrane. After blocking with
5% non-fat milk at room temperature for 1 hr, the transfer
membranes were incubated for 1 hr with primary anti-
bodies specific for HMGB1 (Abcam, MA, USA), prolifer-
ating cell nuclear antigen (PCNA; BD Biosciences, CA,
USA) and β-actin (Cell Signaling, Pickering, ON, CAN-
ADA), respectively. After incubation with peroxidase-
conjugated secondary antibodies for 1 hr at 25°C, the sig-
nals were visualized by 3'-diaminobenzidine detection
(Bio-Rad Laboratories, Hercules, CA, USA) according to
the manufacturer's instructions.
Measurement of cytokine production
The levels of TNF-α and MIP-2 in culture supernatants
were measured by cytokine-specific enzyme-linked
immunosorbent assay (ELISA) using previously validated
DuoSet antibody pairs (R&D Systems, MN, USA) accord-
ing to the manufacturer's instructions.
Statistical analysis
All data are presented as mean ± standard deviation (SD).
The data were analyzed by the t-test (parametric) and by
the Mann-Whitney U test (non-parametric) for compari-
sons between two independent groups. A P value < 0.05
was considered to be statistically significant.
Results
Activation of Fas induces rapid release of HMGB1 from 
viable mϕ
Treatment with recombinant mFasL (0 - 0.5 μg/ml)
induced release of HMGB1, as detected by immunoblot,
from RAW264.7 cells and primary murine peritoneal mϕ
in a dose-dependent manner (Figure 1A). Because LPS is
recognized to be an important stimulus for activation of
HMGB1 release from mϕ [32], the release of HMGB1 was
compared at different times (1-24 hr) following incuba-
tion with mFasL, activating anti-Fas mAb Jo2 (0.25 μg/
ml), and LPS (0.25 μg/ml), respectively (Figure 1B).
In the absence of mFasL, HMGB1 release from wild-
type mϕ was not detected at any time. Following stimula-
tion with either mFasL or mAb Jo2, the concentration of
HMGB1 released into the medium increased overtime.
We observed that the time courses of mFasL and LPS-
induced HMGB1 secretion were different. Whereas
release of HMGB1 following stimulation could be
detected as early as 1 hr following stimulation with
mFasL, LPS-induced release of HMGB1 could not be
detected until 6 hr (Figure 1B).
To demonstrate conclusively that the release of
HMGB1 induced by treatment with either mFasL or mAb
Jo2 is Fas-specific, we performed experiments using mϕ
from Faslpr  mice which are functionally Fas-deficient.
HMGB1 was detected by immunoblot in the culture
supernatant of Faslpr mϕ following treatment with LPS. In
contrast, HMGB1 release could not be detected from
Faslpr mϕ stimulated with either mFasL or mAb Jo2 for 12
hr (Figure 1C).
Because HMGB1 can be released not only passively by
apoptotic and necrotic cells but also by activated mac-
rophages via a death-independent pathway [33,34], viabil-
ity of murine peritoneal mϕ was examined after
incubation with mFasL at various dosages and time
courses. Viability was not significantly affected by incu-
bation with mFasL (0 - 0.5 μg/ml) over a 24 hr time
period (Figure 2A, B), consistent with our previous report
[14]. Similarly, the viability of RAW 264.7 cells was not
affected by overnight incubation with mFasL (0.5 μg/ml)
as previously reported [14]. These results indicate that
Figure 1 Fas activation induces rapid release of HMGB1 from pri-
mary murine peritoneal mϕ and RAW264.7 cells . (A) HMGB1 in cell 
culture-conditioned medium was detected by immunoblot as de-
scribed in Materials and Methods following treatment with recombi-
nant mFasL (0 - 0.5 μg/ml) for 2 hr. (B) HMGB1 in cell culture-
conditioned medium was detected by immunoblot as described in 
Materials and Methods following treatment with mFasL, mAb Jo2 and 
LPS respectively (0.25 μg/ml for each stimulus) for the times indicated 
(0 - 24 hr). (C) HMGB1 in cell culture-conditioned media from primary 
wild-type and Faslpr murine peritoneal mϕs culture-conditioned medi-
um was detected by immunoblot as described in Materials and Meth-
ods following treatment with mFasL, mAb Jo2 and LPS (0.25 μg/ml for 
each stimulus), respectively, for the times indicated (0 - 24 hr). All the 
results are representative of 3 independent experiments that yielded 
similar results.Wang et al. Journal of Inflammation 2010, 7:30
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Fas induces HMGB1 release from mϕ via a mechanism
that does not involve or depend on cell death.
Fas induces translocation of HMGB1 to the cytoplasm of 
mϕ
HMGB1 is a nuclear DNA-binding protein that plays a
functional role in cellular proliferation. In quiescent mϕ,
HMGB1 is confined almost exclusively to the nucleus
[16,17]. However, HMGB1 can be translocated to the
cytoplasm of mϕ following stimulation by specific acti-
v a t i n g  s t i m u l i ,  s u c h  a s  L P S  [ 2 9 ] .  T o  d e t e r m i n e  i f  F a s
induces HMGB1 cytoplasmic translocation, murine peri-
toneal mϕ were collected following incubation with
mFasL (0 - 0.5 μl/ml) for 2 hr. Cytoplasmic and nuclear
extracts were prepared and assyed by specific immunob-
lot for HMGB1, PCNA (a nuclear protein), and β-actin (a
cytoplasmic protein). In quiescent mϕ, HMGB1 was
present in the nucleus but undetectable in the cytoplasm.
HMGB1 increased dramatically in mϕ cytoplasmic
extracts following stimulation with mFasL for 2 hr (Figure
3). These data suggest that Fas induces nuclear-cytoplas-
mic translocation of HMGB1 in mϕ.
Release of HMGB1 contributes to Fas-induced pro-
inflammatory cytokine production by mϕ
Both Fas and HMGB1 have previously been shown to
induce pro-inflammatory cytokine production by mϕ[10-
14,19]. To determine whether HMGB1 contributes to
Fas-induced pro-inflammatory cytokine responses,
mFasL-induced production of TNF-α (Figure 4A) and
MIP-2 (Figure 4B) by wild-type primary murine perito-
neal mϕ was measured following 1 hr pre-treatment with
either anti-HMGB1 neutralizing mAb (0.25 μg/ml) or an
isotype control IgG2b mAb. As expected, the levels of
TNF-α and MIP-2 increased in the culture supernatant
following mFasL stimulation. Fas-induced production of
TNF-α and MIP-2 was significantly decreased by pre-
treatment with inhibitory anti-HMGB1 mAb. These
results indicate that Fas-mediated release of HMGB1
from mϕ contributes significantly to Fas-induced pro-
inflammatory cytokine production by mϕ.
Fas induced production of pro-inflammatory cytokines is 
TLR4-dependent
To investigate the respective roles of TLR2 and TLR4 on
Fas-induced pro-inflammatory cytokine responses, pro-
duction of TNF-α (Figure 5A) and MIP-2 (Figure 5B) was
measured from primary wild-type, Tlr2-/-, and Tlr4-/-
murine peritoneal mϕ incubated with mFasL for 0.5 - 18
hr. TNF-α and MIP-2 production was slightly reduced in
wild-type vs. Tlr2-/- mϕ. In contrast, the production of
both TNF-α and MIP-2 by Tlr4-/-  mϕ was strongly
decreased in comparison to wild-type mϕ. These results
Figure 2 Fas activation for 24 hr does not affect viability of prima-
ry murine peritoneal mϕ. (A) Dose response analysis of viability of pri-
mary murine peritoneal mϕ treated with recombinant mFasL (0-0.5 
μg/ml); (B) time course (0 - 24 hr) analysis of primary peritoneal mϕ fol-
lowing treatment with recombinant mFasL (0.5 μg/ml). Cell viability 
was determined by trypan blue exclusion using a cell viability analyzer 
as described in Materials and Methods. Results are presented as mean 
± SD of 3 independent experiments, n = 3/group. * P ≤ 0.05; **P ≤ 0.01.
Figure 3 Fas activation induces cytoplamsic translocation of 
HMGB1 in primary murine peritoneal mϕ. Primary murine peritone-
al mϕ were stimulated with recombinant mFasL (0 - 0.5 μg/ml) for 2 hr. 
Cytoplasmic and nuclear extracts were prepared as described in Mate-
rials and Methods, and HMGB1 content was determined by immuno-
blot. Equal loading of samples was confirmed by concomitant 
immunoblot analysis of the respective fractions using antibodies spe-
cific for a nuclear (PCNA) or cytoplasmic (β-actin) protein. Blots are rep-
resentative of 3 independent experiments with similar results.Wang et al. Journal of Inflammation 2010, 7:30
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demonstrate that Fas induces pro-inflammatory cytokine
production by mϕ via a TLR4-predominate mechanism,
but do not entirely exclude a minor contribution from a
TLR2-dependent mechanism.
Fas induces HMGB1 release from mϕ via a TLR4/IRAK4-
dependent mechanism
Primary peritoneal murine mϕ from wild-type, Tlr2-/-,
Tlr4-/-, and Irak4-/- mice were used to investigate if Fas-
FasL induced HMGB1 release occurs via a TLR/IRAK4-
dependent mechanism. HMGB1 was detected by immu-
noblot in the culture medium of wild-type and Tlr2-/-, but
not Tlr4-/-, mϕ following incubation with mFasL (Figure
6A). In addition, Fas stimulation failed to induce HMGB1
release from Irak4-/- mϕ (Figure 6B). These results indi-
cate that Fas induces HMGB1 release from mϕ via a
TLR4/IRAK4-dependent mechanism.
Discussion
HMGB1 has been reported to be actively released by mϕ
in response to stimulation with LPS or hydrogen [29,35].
Our results demonstrate that activation of Fas induces
not only active but also rapid release of HMGB1 from via-
ble mϕ via a TLR4/IRAK4-dependent mechanism. Fur-
thermore, the data from this study suggest that released
HMGB1 functions in an autocrine and/or paracrine man-
ner to mediate Fas-induced pro-inflammatory produc-
tion by mϕ. To our knowledge, these data are the first to
implicate HMGB1 in Fas-mediated physiological
responses. These insights significantly advance our
understanding of physiological roles of both the Fas/FasL
system and HMGB1 in activation of host innate immune
responses.
Although generally recognized for its role in mediating
caspase-dependent, apoptotic programmed cell death [1-
3], the Fas/FasL system is increasingly recognized for its
ability to induce pro-inflammatory cytokine production
by mϕ via MyD88-dependent, caspase-independent
mechanisms [13,14,36,37]. A previous study demon-
strated that Fas ligation enhances IL-R1/TLR4 signaling
to promote macrophage-mediated inflammation [36].
Specifically, interruption of Fas-FasL signaling was shown
to suppress both NF-κB activation and cytokine expres-
sion induced by IL-1 and LPS in primary human and
Figure 4 Neutralization of HMGB1 decreases Fas-induced pro-in-
flammatory cytokine production by mϕ. Primary murine peritoneal 
mϕ were pretreated with anti-HMGB1 mAb (0.25 μg/ml) or isotype 
control IgG2b (0.25 μg/ml) for 1 hr, prior to stimulation with mFasL 
(0.25 μg/ml) for the times indicated (0 - 18 hr) as described in Materials 
and Methods. Pro-inflammatory cytokine production was determined 
by measurement of (A) TNF-α (4A) and (B) MIP-2 (4B) in culture super-
natants by cytokine-specific ELISAs as described in Materials and Meth-
ods. Data are presented as mean ± SD of 3 independent experiments, 
n = 3/group. * P ≤ 0.05; **P ≤ 0.01.
Figure 5 Fas-induced pro-inflammatory cytokine production by 
mϕ is TLR4-dependent. Primary murine peritoneal mϕ from wild-
type, Tlr2-/-, and Tlr4-/- mice were treated with mFasL (0.25 μg/ml) for 
the times indicated (0 - 18 hr). Pro-inflammatory cytokine production 
was determined by measurement of (A) TNF-α and (B) MIP-2 in culture 
supernatants by cytokine-specific ELISAs as described in Materials and 
Methods. Data are presented as mean ± SD of 3 independent experi-
ments, n = 3/group. * P ≤ 0.05; **P ≤ 0.01.Wang et al. Journal of Inflammation 2010, 7:30
http://www.journal-inflammation.com/content/7/1/30
Page 6 of 8
murine mϕ [36]. Furthermore, it was suggested that this
cross-talk between Fas and IL-R1/TLR4 was mediated by
interaction of Fas-associated death domain (FADD) with
MyD88. The biological importance of this cross-talk was
supported by another study in which sustained functional
deficiency of the Fas/FasL system in mice attenuated sus-
tained LPS-induced lung inflammation [38].
The release of HMGB1 into the extracellular environ-
ment, where it can function as an endogenous danger sig-
nal or 'alarmin' to promote inflammation has been
implicated in a number of diseases associated with tissue
injury, including sepsis and acute lung injury [28,29]. In
the current study, we demonstrated that activation of Fas
induced rapid (within 1 hr) release of HMGB1 from
RAW264.7 (a murine macrophage cell line) and primary
murine peritoneal mϕ (Figure 1). Similar rapid, active
release HMGB1 has also been reported in experimental
brain ischemia [39]. Following activation of Fas, HMGB1
was detected in the cytoplasm of mϕ, consistent with a
process of nuclear-cytoplasmic translocation as previ-
ously reported for LPS stimulation [40]. Following this
translocation event, HMGB1 was subsequently detected
in the extracellular milieu of mϕ (Figure 3). Importantly,
Fas-induced HMGB1 release was not associated with cell
death (Figure 2) and was remarkably more rapid than
HMGB1 release induced by LPS (Figure 1), a known stim-
ulus for HMGB1 release from mϕ [32,40].
Surprisingly, experiments performed employing
murine mϕ with targeted genetic deletions of Tlr2, Tlr4,
and  Irak4  demonstrated that the Fas/FasL system
induced HMGB1 release primarily via a TLR4/IRAK4-
dependent mechanism (Figure 6). Interestingly, previous
studies have demonstrated TLR4-mediated activation of
HMGB1 translocation and subsequent release of HMGB1
from distinct cell types, including mϕ [29,40-43]. Taken
together, our data are consistent with a proposed 3-step
model for Fas-mediated activation of pro-inflammatory
cytokine production by mϕ: 1) Fas-induced nuclear-cyto-
plasmic translocation of HMGB1; 2) subsequent release
of cytoplasmic HMGB1 by Fas-activated mϕ; and 3) auto-
cine/paracrine-mediated feedback by HMGB1 to activate
TLR4 and promote TLR4/IRAK4-dependent pro-inflam-
matory cytokine production. Based on our observation
that mϕ viability was not affected by Fas activation, we
believe that Fas-mediated HMGB1 release occurs via the
previously described active pathway for HMGB1 release
from viable cells [29,40-43]. This pathway appears to be
calcium/calmodulin-dependent and involve HMGB1
hyperacetylation and/or phosphorylation [28,40-43].
Overall, our findings are consistent with previous reports
that the TLR4/MyD88/IRAK4 complex not only serves to
detect and initiate intracellular signaling in response to
exogenous pathogens but also functions to secrete
HMGB1 from mϕ into the extracellular environment [27-
29,40-43].
Our current study strongly supports a role for HMGB1,
acting as an autocrine and/or paracrine mediator, in Fas-
induced pro-inflammatory cytokine production by mϕ.
Neutralization of HMGB1 using an inhibitory anti-
HMGB1 mAb significantly decreased Fas-induced pro-
duction of TNF-α and MIP-2 by primary murine perito-
neal mϕ (Figure 4). The observation that Fas-induced
production of TNF-α and MIP-2 was markedly decreased
in Tlr4-/- mϕ vs wild-type mϕ (Figure 5) is consistent with
previous reports that HMGB1 may function predomi-
nately as a TLR4 agonist to promote macrophage-medi-
ated inflammation [26,28,30,44,45]. However, our results
do not exclude the possibility that TLR2 and/or RAGE
may serve as receptors for HMGB1 on mϕ [25-27,44].
Previous studies have identified several mechanisms for
Fas-induced pro-inflammatory responses in mϕ. Miwa et
al. reported that Fas induced release of IL-1β from mϕ via
a caspase 1-independent pathway to promote inflamma-
tion [8]. Ma et al. extended our understanding of Fas-
mediated inflammation by demonstrating cross-talk in
mϕ, whereby Fas enhanced signaling via either the IL-1R1
and/or TLR4 pathway to promote chronic inflammation
[36]. Previous studies from our group demonstrated that
Fas could activate pro-inflammatory cytokine production
by mϕ via a MyD88-dependent, caspase-independent
pathway [14]. Our current study has identified a unique
mechanism for Fas-mediated inflammation, in which
HMGB1 is rapidly released by viable mϕ via a TLR4/
IRAK4-dependent mechanism and functions in an auto-
Figure 6 Fas-induced release of HMGB1 by primary murine peri-
toneal mϕ is TLR4/IRAK4-dependent. Primary murine peritoneal mϕ 
derived from (A) wild-type vs Tlr2-/- vs Tlr4-/- mice, or (B) wild-type vs 
Irak4-/- mice, were stimulated with mFasL (0.25 μg/ml) for the times in-
dicated (0 - 6 hr) as described in Materials and Methods. HMGB1 re-
lease into the concentrated cell culture-conditioned medium was 
detected by immunoblot as described in Materials and Methods. Re-
sults are representative of 3 independent experiments that yielded 
similar results.Wang et al. Journal of Inflammation 2010, 7:30
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crine and/or paracrine manner to stimulate pro-inflam-
matory cytokine production.
In summary, this study demonstrates a previously
undescribed mechanism for Fas-mediated inflammation
involving rapid, TLR4/IRAK4-dependent release of pro-
inflammatory HMGB1 from mϕ. Furthermore, our
observations implicate novel physiological cross-talk
between Fas, TLR4, and HMGB1 in the pathogenesis of
mϕ-mediated inflammation. These results suggest the
potential utility of therapeutic interventions directed
against HMGB1 in pathophysiological disease states
associated with mϕ-mediated inflammation and tissue
injury.
About the authors
W. Conrad Liles, M.D., Ph.D. Professor and Vice-Chair of
Medicine; Director, Division of Infectious Diseases;
Senior Scientist, McLaughlin Centre for Molecular Medi-
cine; Senior Scientist, McLaughlin-Rotman Centre for
Global Health; Canada Research Chair in Infectious Dis-
eases and Inflammation; University of Toronto
WCL received his undergraduate education at Williams
College (Williamstown, MA, USA), then entered the
National Institutes of Health (NIH)-sponsored MD-PhD
program (Medical Scientist Training Program) at the
University of Washington and graduated in 1987 with an
MD and PhD in pharmacology. Following residency in
Internal Medicine at Massachusetts General Hospital
from 1987-1990, he returned to the University of Wash-
ington where he served as Chief Medical Resident in 1991
and as a Fellow in Infectious Diseases from 1992-1995. In
1996, he was named to the faculty at the University of
Washington as Assistant Professor of Medicine in the
Division of Allergy and Infectious Diseases and rose to
the rank of Professor of Medicine and Adjunct Professor
of Pathology. In March 2006, WCL moved to the Univer-
sity of Toronto to assume the positions of Vice-Chair of
Medicine and Director, Division of Infectious Diseases.
He was attracted to the University of Toronto by the
opportunities to build translational research programs in
sepsis, inflammation, emerging infectious diseases of
public health importance. He is the recipient of a Canada
Research Chair in Inflammation and Infectious Diseases
and a member of the McLaughlin Centre for Molecular
Medicine, the McLaughlin-Rotman Centre for Global
Health, and the Toronto General Research Institute. As
author of more than 135 peer-reviewed manuscripts and
35 book chapters, WCL maintains an active translational
research program in host defense, inflammation, innate
immunity, sepsis, immunodeficiency disorders, and
immunomodulatory therapy, while serving as a chartered
member of the Immunity and Host Defense Study Sec-
tion of the NIH. In 2004, WCL received the Outstanding
Investigator Award from the Western Society for Clinical
Investigation (WSCI). He has been elected to Fellowship
in the American College of Physicians (ACP) and the
Infectious Diseases Society of America (IDSA).
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
FW and WCL designed the study, performed the experiments, interpreted the
data and drafted the manuscript. ZYL performed animal experiments, and HY
provided essential reagents for conducting the experiments involving neutral-
ization of HMGB1. MH and KCK assisted in study design and interpretation of
data. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by Canada Research Chairs from the Canadian Insti-
tutes of Health Research (WCL and KCK), National Institutes of Health grant P60 
HL73996 (WCL), and research funding from the McLaughlin Centre for Molecu-
lar Medicine, University Health Network, University of Toronto.
Author Details
1Department of Medicine, Toronto General Research Institute, McLaughlin-
Rotman Centre for Global Health, McLaughlin Centre for Molecular Medicine, 
University Health Network, University of Toronto, Toronto, Ontario, Canada and 
2Laboratory of Biomedical Science, the Feinstein Institute for Medical Research, 
Manhasset, NY, USA
References
1. Nagata S: Fas ligand-induced apoptosis.  Annu Rev Genet 1999, 33:29-55.
2. Perl M, Chung CS, Perl U, Lomas-Neira J, de Paepe M, Cioffi WG, Ayala A: 
Fas-induced pulmonary apoptosis and inflammation during indirect 
acute lung injury.  Am J Respir Crit Care Med 2007, 176:591-601.
3. Nagata S: Apoptosis by death factor.  Cell 1997, 88:355-365.
4. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-
Fas) to a cell surface antigen co-downregulated with the receptor of 
tumor necrosis factor.  J Exp Med 1989, 169:1747-1756.
5. Los M, Burek CJ, Stroh C, Benedyk K, Hug H, Mackiewicz A: Anticancer 
drugs of tomorrow: Apoptotic pathways as targets for drug design.  
Drug Discov Today 2003, 8:67-77.
6. Everett H, McFadden G: Apoptosis: An innate immune response to virus 
infection.  Trends Microbiol 1999, 7:160-165.
7. Hamann KJ, Dorscheid DR, Ko FD, Conforti AE, Sperling AI, Rabe KF, White 
SR: Expression of Fas (CD95) and FasL (CD95L) in human airway 
epithelium.  Am J Respir Cell Mol Biol 1998, 19:537-542.
8. Miwa K, Asano M, Horai R, Iwakura Y, Nagata S, Suda T: Caspase 1-
independent IL-1beta release and inflammation induced by the 
apoptosis inducer Fas ligand.  Nat Med 1998, 4:1287-1292.
9. Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, 
Jonas M, Martin TR: Soluble Fas ligand induces epithelial cell apoptosis 
in humans with acute lung injury (ARDS).  J Immunol 1999, 
163:2217-2225.
10. Jung DY, Lee H, Jung BY, Ock J, Lee MS, Lee WH, Suk K: TLR4, but not 
TLR2, signals autoregulatory apoptosis of cultured microglia: a critical 
role of IFN-beta as a decision maker.  J Immunol 2005, 174:6467-6476.
11. Neff TA, Guo RF, Neff SB, Sarma JV, Speyer CL, Gao H, Bernacki KD, Huber-
Lang M, McGuire S, Hoesel LM, Riedemann NC, Beck-Schimmer B, 
Zetoune FS, Ward PA: Relationship of acute lung inflammatory injury to 
Fas/FasL system.  Am J Pathol 2005, 166:685-694.
12. Oliveira GM, Diniz RL, Batista W, Batista M, Bani M, Correa C, de Araújo-
Jorge TC, Henriques-Pons A: Fas ligand-dependent inflammatory 
regulation in acute myocarditis induced by Trypanosoma cruzi 
infection.  Am J Pathol 2007, 171:79-86.
13. Park DR, Thomsen AR, Frevert CW, Pham U, Skerrett SJ, Kiener PA, Liles WC: 
Fas (CD95) induces proinflammatory cytokine responses by human 
monocytes and monocyte-derived macrophages.  J Immunol 2003, 
170:6209-6216.
Received: 14 August 2009 Accepted: 17 June 2010 
Published: 17 June 2010
This article is available from: http://www.journal-inflammation.com/content/7/1/30 © 2010 Wang et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Inflammation 2010, 7:30Wang et al. Journal of Inflammation 2010, 7:30
http://www.journal-inflammation.com/content/7/1/30
Page 8 of 8
14. Altemeier WA, Zhu X, Berrington WR, Harlan JM, Liles WC: Fas (CD95) 
induces macrophage proinflammatory chemokine production via a 
MyD88-dependent, caspase-independent pathway.  J Leukoc Biol 2007, 
82:721-728.
15. Comings DE, Harris DC: Nuclear proteins. II. Similarity of nonhistone 
proteins in nuclear sap and chromatin, and essential absence of 
contractile proteins from mouse liver nuclei.  J Cell Biol 1976, 70:440-452.
16. Smerdon MJ, Isenberg I: Interactions between the subfractons of calf 
thymus H1 and nonhistone chromosomal proteins HMG1 and HMG2.  
Biochemistry 1976, 15:4242-4247.
17. Bustin M: Regulation of DNA-dependent activities by the functional 
motifs of the high mobility group chromosomal proteins.  Mol Cell Biol 
1999, 19:5237-5246.
18. Bianchi ME, Beltrame M: Upwardly mobile proteins. Workshop: the role 
of HMG proteins in chromatin structure, gene expression and 
neoplasia.  EMBO Rep 2000, 1:109-114.
19. Scaffidi P, Misteli T, Bianchi ME: Release of chromatin protein HMGB1 by 
necrotic cell triggers inflammation.  Nature 2002, 418:191-195.
20. Wang H, Yang H, Czura CJ, Sama AE, Tracey KJ: HMGB1 as late mediator 
of lethal systemic inflammation.  Am J Respir Crit Care Med 2001, 
164:1768-1773.
21. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-
Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility 
group 1 protein (HMG1) stimulates proinflammatory cytokine 
synthesis in human monocytes.  J Exp Med 2000, 192:565-570.
22. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, 
Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, Maruyama I: 
High mobility group box chromosomal protein 1 plays a role in the 
pathogenesis of rheumatoid arthritis as a novel cytokine.  Arthritis 
Rheum 2003, 48:971-981.
23. Andersson A, Covacu R, Sunnemark D, Danilov AI, Dal BA, Khademi M, 
Wallström E, Lobell A, Brundin L, Lassmann H, Harris RA: Pivotal advance: 
HMGB1 expression in active lesions of human and experimental 
multiple sclerosis.  J Leukoc Biol 2008, 84:1248-1255.
24. Klune JR, Dhupar R, Cardinal J, Billiar TR, Tsung A: HMGB1: endogenous 
danger signaling.  Mol Med 2008, 14:476-484.
25. Stern D, Yan SD, Yan SF, Schmidt AM: Receptor for advanced glycation 
endproducts: a multiligand receptor magnifying cell stress in diverse 
pathologic settings.  Adv Drug Deliv Rev 2002, 54:1615-1625.
26. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim 
D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: 
Involvement of TLR2 and TLR4 in cellular activation by high mobility 
group box 1 protein (HMGB1).  J Biol Chem 2004, 279:7370-7376.
27. Van Beijnum JR, Buurman WA, Griffioen AW: Convergence and 
amplification of toll-like receptor (TLR) and receptor for advanced 
glycation end products (RAGE) signaling pathways via high mobility 
group B1 (HMGB1).  Angiogenesis 2008, 11:91-99.
28. Youn JH, Oh YJ, Kim ES, Choi JE, Shin JS: High mobility group box 1 
protein binding to lipopolysaccharide facilitates transfer of 
lipopolysaccharide to CD14 and enhances lipopolysaccharide-
mediated TNF-alpha production in human monocytes.  J Immunol 
2008, 180:5067-5074.
29. Tsung A, Klune JR, Zhang X, Jeyabalan G, Cao Z, Peng X, Stolz DB, Geller 
DA, Rosengart MR, Billiar TR: HMGB1 release induced by liver ischemia 
involves Toll-like receptor 4 dependent reactive oxygen species 
production and calcium-mediated signaling.  J Exp Med 2007, 
204:2913-2923.
30. Fan J, Li Y, Levy RM, Fan JJ, Hackam DJ, Vodovotz Y, Yang H, Tracey KJ, 
Billiar TR, Wilson MA: Hemorrhagic shock induces NAD (P)H oxidase 
activation in neutrophils: role of HMGB1-TLR4 signaling.  J Immunol 
2007, 178:6573-6580.
31. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of 
octamer binding proteins with "mini-extracts", prepared from a small 
number of cells.  Nuclear Acids Res 1989, 17:6419.
32. El Gazzar M: HMGB1 modulates inflammatory responses in LPS-
activated macrophages.  Inflamm Res 2007, 56:162-167.
33. Jiang W, Pisetsky DS: The induction of HMGB1 release from RAW 264.7 
cells by transfected DNA.  Mol Immunol 2008, 45:2038-2044.
34. Kawahara K, Setoyama K, Kikuchi K, Biswas KK, Kamimura R, Iwata M, Ito T, 
Morimoto Y, Hashiguchi T, Takao S, Maruyama I: HMGB1 release in co-
cultures of porcine endothelial and human T cells.  Xenotransplantation 
2007, 14:636-641.
35. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, Xiao X: Hydrogen peroxide 
stimulates macrophages and monocytes to actively release HMGB1.  J 
Leukoc Biol 2007, 81:741-747.
36. Ma Y, Liu H, Tu-Rapp H, Thiesen HJ, Ibrahim SM, Cole SM, Pope RM: Fas 
ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling 
and promotes chronic inflammation.  Nat Immunol 2004, 5:380-387.
37. Imtiyaz HZ, Rosenberg S, Zhang Y, Rahman ZS, Hou YJ, Manser T, Zhang J: 
The Fas-associated death domain protein is required in apoptosis and 
TLR-induced proliferative responses in B cells.  J Immunol 2006, 
176:6852-6861.
38. Matute-Bello G, Winn RK, Martin TR, Liles WC: Sustained polysaccharide-
induced lung inflammation in mice is attenuated by functional 
deficiency of the Fas/Fas ligand system.  Clin Diag Lab Immunol 2004, 
11:358-361.
39. Qiu J, Nishimura M, Wang Y, Sims JR, Qiu S, Savitz SI, Salomone S, 
Moskowitz MA: Early release of HMGB-1 from neurons after the onset of 
brain ischemia.  J Cereb Blood Flow Metab 2008, 28:927-938.
40. Pisetsky DS, Jiang W: Role of Toll-like receptors in HMGB1 release from 
macrophages.  Ann N Y Acad Sci 2007, 1109:58-65.
41. Bonaldi TF, Talamo F, Scaffaldi D, Ferea D, Poto A, Bachi A, Rubartelli A, 
Agresti A, Bianchi ME: Monocytic cells hyperacetylate chromatin protein 
HMGB1 to redirect it towards secretion.  EMBO J 2003, 22:5551-5560.
42. Jiang W, Li J, Gallowitsch-Puerta M, Tracey KJ, Pisetsky DS: The effects of 
CpG DNA on HMGB1 release by murine macrophage cell lines.  J Leukoc 
Biol 2005, 78:930-936.
43. Zhang X, Wheeler D, Tang Y, Guo L, Shapiro RA, Ribar TJ, Means AR, Billiar 
TR, Angus DC, Rosengart MR: Calcium/calmodulin-dependent protein 
kinase (CaMK) IV mediates nucleocytoplasmic shuttling and release of 
HMGB1 during lipopolysaccharide stimulation of macrophages.  J 
Immunol 2008, 181:5015-5023.
44. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim 
D, Sohn JW, Yamada S, Maruyama I, Banerjee A, Ishizaka A, Abraham E: 
High mobility group box 1 protein interacts with multiple Toll-like 
receptors.  Am J Physiol Cell Physiol 2005, 290:17-24.
45. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey 
KJ, Yang H: HMGB1 signals through Toll-like receptor 4.  Shock 2006, 
26:174-17 9.
doi: 10.1186/1476-9255-7-30
Cite this article as: Wang et al., Fas (CD95) induces rapid, TLR4/IRAK4-depen-
dent release of pro-inflammatory HMGB1 from macrophages Journal of 
Inflammation 2010, 7:30